Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer

Summary

The purpose of this project is to examine whether treatment with vandetanib has an effect on the tumor cells in breast cancer by examining tissue markers.

Timeline

Start

2013-10

Primary completion

2018-12-21

Completion

2018-12-21

Outcome

Missed primary endpoint

Stopped: “Drugs unavailable”

registry analysis (superiority test); Vandetanib vs Placebo; p = 0.51; t-test, 2 sided NCT01934335 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vandetanib	Small molecule	300 mg	Oral

Indications